Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
University of Chicago
Summary
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Must have a medical diagnosis of malignant mesothelioma that has been confirmed by a physician. * Participant must be able to sign a consent form stating that they choose (of their own free will) to participate in the study and agree to follow the study requirements and restrictions that are listed in the consent form. * Must be willing to sign and date consent form before any mandatory study-specific procedures, sample collecting and tests. * Willing to experience genetic testing to determine study eligibility. Must be willing to genetically test tumor and normal body c…
Interventions
- DrugOlaparib
Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.
Location
- University of Chicago Medical CenterChicago, Illinois